Clinical trials: Androgens
Acne Vulgaris
Clascoterone Versus Clindamycin Added to Adapalene/Benzoyl Peroxide for Moderate Facial Acne
This randomised trial compares two treatments added to the same standard acne gel in people with moderate facial acne. All participants will use adapalene 0.1%/benzoyl peroxide 2.5% gel at night.
- Trial name
- CLASCO-ACNE (NCT07881315)
- Testing
- Clascoterone 1% cream, Clindamycin 1% lotion, Adapalene 0.1%/benzoyl peroxide 2.5% gel
- Where
- Pakistan
- Volunteers
- 118 people
- Sponsor
- Allied Hospital Faisalabad
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy of [177Lu]Lu-PSMA-617 over a change of androgen receptor-directed therapy (ARDT) treatment in prolonging radiographic progression free survival (rPFS) in Chinese metastatic…
- Trial name
- NCT05658003
- Testing
- [177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11
- Where
- 15 sites in China
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy
Background: Pox viral vectors can induce a PSA-specific T-cell responses and clinical responses in patients with advanced prostate cancer.
- Trial name
- NCT00096551
- Testing
- Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM), Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM), Recombinant Fowlpox-GM-CSF
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Castration-resistant Prostate Cancer, Metastatic Cancer
Predictive Nomogram of CRPC
This is an observational, prospective (study following participants forward in time), multi-center (study conducted in more than 1 center) study to identify the risk factors, then develop and validate the predictive Nomogram of…
- Trial name
- CRPC-PN (NCT03177551)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Second Hospital
Prostate Cancer
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy may be effective treatment for prostate cancer.
- Trial name
- NCT00002651
- Testing
- bicalutamide, goserelin acetate, clinical observation
- Where
- 14 sites in Canada
- Volunteers
- 3,040 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
The purpose of this research study is to evaluate a newer imaging technique, called 18F-Sodium Fluoride (NaF) positron emission tomography (PET). NaF is a tracer (dye) that is very sensitive for changes in bone.
- Trial name
- NaFl PET/CT (NCT01516866)
- Testing
- Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Docetaxel in Treating Patients With Relapsed Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482274
- Testing
- docetaxel
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Hypogonadism, Estrogens
Development and Validation of in Vitro Cell-based Bioassays for Nuclear Receptor Activation
This is a prospective biobank set up to collect serum from patients with disorders associated with changes in androgens, estrogens or sex hormone-binding globulin (SHBG), before and/or after treatment.
- Conditions
- Hypogonadism, Estrogens, Testosterone, Androgens
- Trial name
- NCT02434562
- Testing
- Serum (with or without urine) samples
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
This phase II trial studies the side effects and how well abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy works in treating patients with localized or locally advanced…
- Conditions
- Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- RAD1 (NCT01023061)
- Testing
- abiraterone acetate, prednisone, leuprolide acetate
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Washington
Premenstrual Syndrome
Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder
This study will evaluate the effectiveness of flutamide in reducing symptoms of premenstrual dysphoric disorder.
- Trial name
- NCT00611923
- Testing
- Flutamide
- Volunteers
- 115 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00567580
- Testing
- PBRT, PLNRT, AA
- Where
- 460 sites in United States, Canada and 2 more
- Volunteers
- 1,792 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Stage IV Prostate Cancer
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer (mCSPC).
- Conditions
- Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer, Adenocarcinoma of the Prostate
- Trial name
- NCT03511196
- Testing
- Adaptive Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease.
- Trial name
- NCT07237269
- Testing
- Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- University of Nebraska
Prostate Cancer
Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.
- Trial name
- DARIUS (NCT05346848)
- Testing
- Association of darolutamide and EBRT, Association of ADT and EBRT
- Where
- 10 sites in France
- Volunteers
- 62 people
- Sponsor
- Institut Bergonié
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor…
- Trial name
- NCT01889238
- Testing
- Enzalutamide
- Where
- 132 sites in United States, Belgium and 5 more
- Volunteers
- 118 people
- Sponsor
- Pfizer
Prostate Cancer
Comparison of PET Imaging Patterns With PSMA and AR Expression in Prostate Cancer and Bladder Cancer
Patients suffering either from newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer (cohort A), metastatic castration-resistant prostate cancer (mCRPC, cohort B), newly diagnosed postate cancer…
- Trial name
- NCT05109884
- Testing
- PSMA PET Scan, FDHT PET Scan
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Cancer of the Breast, Breast Cancer
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
The goal of this clinical study is to determine the safety, pharmacokinetics, pharmacodynamics and efficacy and activity of seviteronel, a lyase-selective inhibitor of CYP17, in patients with advanced breast cancer.
- Conditions
- Cancer of the Breast, Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- CLARITY-01 (NCT02580448)
- Testing
- Seviteronel
- Where
- 36 sites in United States
- Volunteers
- 175 people
- Sponsor
- Innocrin Pharmaceutical
Prostate Cancer
Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258284
- Testing
- capecitabine, docetaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Locally Advanced Malignant Neoplasm
Healthy Bones Study
Prostate cancer patients receiving hormone treatment (androgen deprivation therapy, or ADT) are at increased risk of developing bone loss and osteoporosis as side effects.
- Trial name
- NCT01973673
- Testing
- Bone health educational materials
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
- Trial name
- NCT01251861
- Testing
- Akt Inhibitor MK2206, Bicalutamide, Clinical Observation
- Where
- 198 sites in United States, Ireland
- Volunteers
- 108 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.